Podocarpusflavone A sensitizes MASLD-related hepatocellular carcinoma to lenvatinib by targeting ABAT and ALDH2
Clinical and Molecular Hepatology · 17.11.2026
DOI: 10.3350/cmh.2026.0743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 17.11.2026. Verfasst von Bing Quan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan Uni….
Abstract (Originalsprache)
Background/aims: Despite the rising global incidence of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC), immunotherapy offers limited survival benefits in this non-viral etiology, positioning lenvatinib as a critical treatment that necessitates novel strategies to enhance its efficacy. This study aimed to identify MASLD-HCC signature genes and to explore a novel agent to overcome lenvatinib resistance.
Methods
Single-cell RNA sequencing identified signature genes, validated by immunohistochemistry, qPCR, Western blot, and spatial transcriptomics in human and murine specimens. Virtual screening identified a natural compound targeting hub genes. Direct binding was confirmed using molecular dynamics simulations, cellular thermal shift assays, and surface plasmon resonance. Therapeutic efficacy and underlying mechanisms were comprehensively evaluated in vitro under lipotoxic stress conditions and in vivo using diet-induced orthotopic MASLD-HCC mouse models.
Results
A 170-gene signature was established, with ABAT and ALDH2 prioritized as hub genes. Podocarpusflavone A (PCFA) emerged as a dual-targeting agent that robustly reverses acquired lenvatinib resistance. Instead of increasing protein abundance, PCFA directly binds these targets, which is accompanied by markedly enhanced cellular ABAT and ALDH activities. This diminishes the protective GABA shield and disrupts the mitochondrial NAD⁺ balance, precipitating a lethal mitochondrial superoxide burst and inhibiting key oncogenic pathways. In vivo, the PCFA and lenvatinib combination profoundly suppressed orthotopic tumor progression and was associated with short-term improvements in hepatic steatosis and fibrosis-related histological findings, with no evident toxicity under the conditions tested.
Conclusions
PCFA combined with lenvatinib represents a promising strategy for MASLD-HCC and provides mechanistic insights into its antitumor activity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai 200032, China.
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Medical Oncology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou 510180, Guangdong, China.
- Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
- Research Unit of Liver Cancer Recurrence and Metastasis, Chinese Academy of Medical Sciences, Beijing, China.
Zitieren
APA
Quan, B., Lu, Y., Cao, Y., Chen, S., Shao, Y., Cai, J., Zhang, P., Cai, Y., Zhu, G., Wang, B., Yang, Y., Du, J., Zhou, J., Fan, J., Zhang, Y., Li, J., & Dai, Z. (2026). Podocarpusflavone A sensitizes MASLD-related hepatocellular carcinoma to lenvatinib by targeting ABAT and ALDH2. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0743
Vancouver
Quan B, Lu Y, Cao Y, Chen S, Shao Y, Cai J, et al. Podocarpusflavone A sensitizes MASLD-related hepatocellular carcinoma to lenvatinib by targeting ABAT and ALDH2. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0743
BibTeX
@article{Quan2026,
author = {Quan, Bing and Lu, Yongjiang and Cao, Yining and Chen, Shiping and Shao, Yujie and Cai, Jialiang and Zhang, Peiling and Cai, Yufan and Zhu, Guiqi and Wang, Biao and Yang, Yi and Du, Junxian and Zhou, Jian and Fan, Jia and Zhang, Yan and Li, Jinghuan and Dai, Zhi},
title = {Podocarpusflavone A sensitizes MASLD-related hepatocellular carcinoma to lenvatinib by targeting ABAT and ALDH2},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0743}
}
EUVIMED